Page 42 - Planegg News Today

19.04.2021 - 16:03 Uhr MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution MorphoSys AG, DE0006632003Notification of Major Holdings 1. Details of issuer Name: MorphoSys AG Street: Semmelweisstr. 7 Postal code: 82152 City: PlaneggGermany Legal Entity Identifier (LEI): 529900493806K77LRE72 2. Reason for notification ? Acquisition/disposal of shares with voting rights X Acquisition/disposal o...

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma Respiratory tract infection These are not all the possible side effects of MONJUVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Before you receive MONJUVI, tell your healthcare provider about all your medical cond...

MorphoSys AG: Invitation to MorphoSys Full Year Results 2020 Conference Call on March 16, 2021 Conference Call Alert PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 9, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein, and peptide technologies, will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT). MorphoSys Management team will host a conf...

Bruker announces new results in deep, unbiased plasma proteomics, PaSER 1.1 software and new cross-linking consumables at US HUPO 2021 At the virtual 17 th US HUPO Conference (US HUPO 2021), Bruker Corporation (Nasdaq: BRKR) today announces progress with several collaborations in deep, unbiased plasma proteomics, leveraging the speed, sensitivity and dynamic range of 4D proteomics on timsTOF Pro systems.   Figure 1. Large-scale peptide CCS measurement with TIMS and PASEF. www.nature.com/articl...

Investegate announcements from MorphoSys AG, Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance

MorphoSys AG / Key word(s): Annual ResultsAd hoc: MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance01-March-2021 / 22:14 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is sole...

Electrochaea from Germany delivers renewable methane technology 90,000 tons of CO 2 savedper year and per plant Project investment of 150 million euro for the construction of the pilot plant With the aim of drastically reducing the high CO 2 emissions inlime and cement production, the power‐to‐methane specialist Electrochaea is working together with the Belgian lime producer Carmeuse, the energy company Engie, the Engie subsidiary Storengy, and the mechanical and plant engineering group Jo...

Search jobs 25-Jan-2021 MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 25.01.2021 / 22:00 Media Release MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer PLANEGG/MUNICH, Germany and SHANGHAI, China - January 25, 2021 - MorphoSys (FSE: MOR; Pr...

Share this article Share this article SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX;NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States. ...

(3) PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / January 25, 2021 / MorphoSys (FSE:MOR)(Prime Standard Segment, MDAX & TecDAX)(NASDAQ:MOR) and I-Mab (IMAB) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MOR210/ TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States. MOR210/TJ210 is a monoclonal antibody dev...